Background
Hemophilia is a rare genetic disorder that affects the ability to clot blood properly. The two main types of hemophilia are Hemophilia A and Hemophilia B. Differential diagnosis includes bleeding conditions such as von Willebrand disease, thrombocytopenia, and disseminated intravascular coagulation (DIC), which can cause abnormal bleeding.
Definition/Origin of Disorder and Statistics
Hemophilia is a sporadic genetic disorder that affects the ability of the blood to clot as expected. It occurs due to a deficiency or dysfunction of clotting factors in the blood, specifically factor VIII or factor IX. Hemophilia A and Hemophilia B are caused by a deficiency of clotting factor VIII and clotting factor IX, respectively (Johnsen, 2022). Hemophilia is inherited from the mother through an X-linked recessive pattern. Hemophilia occurs in about 1 in 5,000 male births and is much less common in females (Johnsen, 2022).
Signs and Symptoms
Symptoms of hemophilia can vary in severity depending on the degree of deficiency in the clotting factor. Individuals with hemophilia tend to bleed easily and for a longer time than others. They may experience excessive bleeding from cuts, nosebleeds, and easy bruising. Hemophiliacs may also experience joint pain and swelling due to internal bleeding (Abrol, 2019). In severe cases, bleeding can occur spontaneously or after a minor injury. The most common site for spontaneous bleeding is the knee, ankle, or elbow.
Examination Findings
Physical examination can indicate signs of bleeding, such as bruises, hematomas, and joint effusions. The joints may be swollen, warm to the touch, and tender. Indications of joint destruction, limited motion range, and deformities may be present in severe cases. Signs of bleeding, such as blood in the urine or stool, and a brain hemorrhage may occur (Abrol, 2019). Laboratory tests for individuals with hemophilia always indicate lower levels of clotting factors.
Diagnostics and Treatment
Diagnosis of hemophilia is typically made through blood tests that measure clotting factor levels. Blood tests can measure the levels of clotting factors VIII and IX to confirm the diagnosis, which can be supported by genetic testing. Hemophilia treatment includes replacement therapy with the deficient clotting factor through infusion or gene therapy. Replacement therapy involves infusing a concentrate of the deficient clotting factor into the bloodstream to ensure proper blood clotting (Abrol, 2019). This should be performed regularly to avert bleeding episodes and regulate medical emergencies.
For Hemophilia A: Antihemophilic factor (recombinant) and Antihemophilic factor (human) are two commonly used medications for replacement therapy. The dosage and frequency of infusions will depend on the severity of the disorder and the individual’s response to treatment (Abrol, 2019).
For Hemophilia B: Coagulation factor IX (recombinant) and Coagulation factor IX (human) are the medications used for replacement therapy. They are given as an infusion into a vein, usually through a central venous catheter. Dosage and frequency of infusions are tailored to the individual, varying based on the disorder’s severity and the patient’s treatment response. Desmopressin (DDAVP), a synthetic hormone, can be given as a nasal spray or injection to increase the release of clotting factors from the blood vessels (Sanchez-Lara & Valentino, 2022). Tranexamic acid can control bleeding by inhibiting the breakdown of blood clots.
Need to Know Highlights
Hemophilia is a chronic condition that requires ongoing management throughout a person’s lifetime. Patients should be aware of the signs of bleeding and seek prompt medical attention if they experience any of these signs. Regular monitoring of clotting factor levels and joint health is important. A comprehensive care team, including a hematologist, physical therapist, and dental care, is necessary for proper management. People with hemophilia should carry an identification card that indicates they have a bleeding disorder and emergency contact information.
Red Flags Other Pertinent Information
The red flags include prolonged and recurrent bleeding after surgery, when brushing teeth, and muscle weakness. Large bruises in unusual locations can signify severe deterioration (Johnsen, 2022). Other pertinent details include the need to understand the family history of bleeding disorders, as well as the use of clotting factor assays and laboratory tests as part of the medical examination and diagnosis. Hemophilic patients should be aware of the danger signs that indicate the need for assistance.
References
Abrol, P. (2019). Introductory Chapter: Hemophilia. In Hemophilia-Recent Advances. IntechOpen.
Johnsen, J. M. (2022). Current challenges in hemophilia genetics and how they can be overcome. Nature Cardiovascular Research, 1(10), 867-868.
Sanchez-Lara, P. A., & Valentino, L. A. (2022). Advances in Hemophilia Treatment. Springer, Cham.